Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

Empowering Drug Discovery through Genomics

The NHS may soon be able to identify your risk of heart disease or a stroke well before it happens by studying your DNA.